What's in KYU-SUNG LEE's pipeline?

KYU-SUNG LEE has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with KYU-SUNG LEE's portfolio?

Top competitors by shared drug class: Oupushifang Pharmaceutical Technology Co., Ltd., Pfizer's Upjohn has merged with Mylan to form Viatris Inc., R-Pharm, University of California, San Francisco.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kyu-sung-lee.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

KYU-SUNG LEE — Portfolio Competitive Intelligence Brief

KYU-SUNG LEE pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Alpha blocker	Alpha blocker	marketed
Tolterodine 6	Tolterodine 6	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic receptors	Urology

Therapeutic area mix

Urology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Oupushifang Pharmaceutical Technology Co., Ltd. · 1 shared drug class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 shared drug class
R-Pharm · 1 shared drug class
University of California, San Francisco · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for KYU-SUNG LEE:

Cite this brief

Drug Landscape (2026). KYU-SUNG LEE — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kyu-sung-lee. Accessed 2026-05-16.